Mark Gainor
Chairman
Mark presently serves as a Board member with MarkOne Financial, one of the principal investments by Lucor Holdings, LLC, a private venture capital investment company investing primarily in financial services and health care technology companies.
Mark has over 30 years of experience in developing and operating healthcare companies, commercializing new products on a global basis and sourcing and investing in innovative healthcare technologies.
In 1974, Mark and his father co-founded Gainor Medical Canada, a diabetic and medical supply distribution company. For the next 10 years they successfully operated and expanded throughout Canada, successfully growing sales at a compound annual growth rate in excess of 70%.
In 1984, Mark took the company international, expanded operations to Long Beach, California, and formed Gainor Medical USA, a multi-national manufacturer and distributor of diabetic supplies. While President and CEO of Gainor Medical, he expanded the company into six separate divisions and increased sales to over $100 million.
Although he was competing against well capitalized multi-national companies such as Becton Dickinson and Sherwood Medical/Tyco, by constantly innovating and focusing on tailoring a commodity product into a specific end use device, Mark was able to globalize and revolutionize the business and as a result, capture over 1/3rd of the global market for blood sampling products. Utilizing his deep diabetes industry knowledge and extensive network, Mark was able to bring business segments together and make Gainor Medical a world-wide supplier for companies such as Lifescan (Johnson & Johnson), Becton Dickinson, Boehringer Mannheim, Roche Diagnostics and Bayer.
In January 1999, the company was acquired for approximately $170 million by Matria Healthcare, Inc. (MATR), a public disease management company and renamed Facet Technologies LLC. For approximately one year, Mark served as President of the Diabetes Division of this corporation. In 2001, Mark left the company to establish Lucor Holdings, LLC.
Mark presently serves or has served on the Boards of the following companies:
Therasense (THER): Mark was an early stage venture investor and Board member of this healthcare technology company dedicated to improving glucose monitoring. The company grew sales from $5 million in 2000 to over $200 million in 2003 and became the worldwide market leader in alternative site glucose testing. In 2004 the company was acquired by Abbott Laboratories for $1.2 billion.
Adams Laboratories (ARXT): Mark was an early venture investor, Board member and interim-CEO in this pharmaceutical company that developed, marketed and sold prescription pharmaceutical products specializing in the ear, nose, throat and allergy markets. The company received the first ever approval by the FDA for a long acting guaifenesin product. In 2003, Mark was asked to serve as Interim Chief Executive Officer. In this capacity, Mark was instrumental in restructuring, refocusing and transitioning the business and raising the company?s final capital round. Shortly thereafter, Adams went public and currently has a market capitalization exceeding $1.4 billion.
Venetec International: Mark was an early stage venture investor and Board member in this company that was a world leader in catheter securement technology. In 2005, the company was sold to C.R. Bard for approximately $170 million.
Matria Healthcare (MATR), a publicly traded company that is the industry leader in providing population-based disease management programs, health services and supplies for women?s health, diabetes, cardiovascular disease and respiratory disorders. The company serves health plans and employers through offices in the United States and internationally.
Mark One Financial: Mark was a founding investor, Chairman and CEO in this private company providing financing and insurance solutions to the automobile sector.
Mark graduated from the University of Alberta, Canada with a degree in Business Administration and Commerce.